Andere Sprachen Ocular Therapeutix, Inc.

Aktien

A1180P

US67576A1007

OCUL

Realtime-Estimate Cboe BZX Andere Börsenplätze 21:28:12 02.05.2024			% 5 Tage	% 1. Jan.
5,845 ^USD	+16,43 %		+38,10 %	+30,04 %

18.04.	Ocular Therapeutix, Inc. gibt positive Topline-Daten der Phase 1 für AXPAXLI? bei diabetischer Retinopathie bekannt	CI
15.04.	Ocular Therapeutix, Inc. kündigt Änderungen in der Geschäftsführung an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024	01.05.
Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy	19.04.
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	18.04.
Ocular Therapeutix : Amendment No. 3 to 2019 Inducement Stock Incentive Plan - Form 8-K	18.04.
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	18.04.
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy	18.04.
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy	18.04.
Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO	16.04.
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders	16.04.
Ocular Therapeutix CEO Antony Mattessich Steps Down; Pravin Dugel Named Successor	15.04.
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO	15.04.
Ocular Therapeutix, Inc. Announces Executive Changes	15.04.
Ocular Therapeutix, Inc. Announces CEO Changes	15.04.
Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4) to Senior Vice President of Global Head of Biometrics	10.04.
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics	09.04.
Ocular Therapeutix Announces Positive Phase 2 PAXTRAVA Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting	08.04.
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting	06.04.
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting	06.04.
Ocular Therapeutix to Present Data at the 2024 ASCRS Annual Meeting	27.03.
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)	26.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ocular Therapeutix, Inc.

Aktien

A1180P

US67576A1007

OCUL

Andere Sprachen

Filter